STTK - NASDAQ
Shattuck Labs, Inc.
$4.89
+0.43%Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
At a Glance
Live SnapshotShattuck Labs, Inc. Management Team
Ms. Casi DeYoung
Chief Business Officer
Compensation
$523,482
Mr. Andrew R. Neill M.B.A.
Chief Financial Officer
Compensation
$581,936
Dr. Arunthathy Nirmalini Pandite M.B.A., M.D.
Chief Medical Officer
Compensation
$639,654
Dr. Abhinav A. Shukla Ph.D.
Chief Technical Officer
Compensation
$567,398
Mr. George Fromm Ph.D.
Co-Chief Scientific Officer
Mr. Suresh de Silva Ph.D.
Co-Chief Scientific Officer
Dr. Taylor H. Schreiber M.D., Ph.D.
Co-Founder, Chief Executive Officer & Director
Compensation
$742,560
Dr. Stephen Stout J.D., Ph.D.
General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer
Dr. Thomas Lampkin Pharm.D.
Senior Vice President of Regulatory Affairs
Mr. Conor Richardson CPA
Vice President of Investor Relations
Shattuck Labs, Inc. Insider Positioning
During the last 12 months, insiders have purchased $5.08M and sold $213K worth of STTK shares, resulting in $4.86M of net buying activity.
3 Months
0
0.00
32.0K
212.54K
-213K
-$213K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
4.8M
5.08M
0
0.00
+5.1M
+$5.08M
Top Buyers
Redmile Group, Llc
Director, 10 Percent Owner:
$4.47M
Siegall Clay B
Director
$166K
Neill Andrew R
Officer: Chief Financial Officer
$69K
Ashiya Mona
Director
$66K
Baker Daniel G.
Director
$66K
Top Sellers
Pandite Arundathy N.
Officer: Chief Medical Officer
$198K
Shukla Abhinav A.
Officer: Chief Technical Officer
$14K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $4.86M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
STTK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 08, 2026 | May 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | May 21, 2025 | July 10, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 06, 2023 | May 23, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | June 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 22, 2021 | June 08, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.